Trazodone Safety in Older Adults (50 to 64): Risks, Dosing, and What Your Doctor Should Monitor

Print or save as PDF

See the public record for Trazodone

What is trazodone actually approved for?

Trazodone is a prescription antidepressant that current US labeling describes as a selective serotonin reuptake inhibitor and a 5-HT2 receptor antagonist; chemically it is a triazolopyridine derivative, not a tricyclic [1]. It is not a controlled substance [1]. The label lists one indication, major depressive disorder in adults, and states the drug is not approved for pediatric patients [1]. There is no insomnia indication and no insomnia dose in the label, so sleep use is off-label [1].

Labeled depression dosing starts at 150 mg/day in divided doses and rises by 50 mg/day every 3 to 4 days, to a usual outpatient maximum of 400 mg/day; severely depressed inpatients may receive up to 600 mg/day [1]. Tablets are taken shortly after a meal or light snack, swallowed whole or broken along the score line, and not chewed or crushed [1]. When the drug is discontinued, the label calls for gradual dose reduction rather than abrupt stopping [1].

On sleep, Mendelson's 2005 review in the Journal of Clinical Psychiatry identified 18 studies of trazodone for insomnia and concluded the evidence was very limited: most studies were small, conducted in depressed patients, and often lacked objective sleep measures [4]. That review judged it uncertain whether the risk-benefit balance favors trazodone in nondepressed people with insomnia, and described it at the time as the second most commonly prescribed agent for insomnia [4].

Does the 50-to-64 group count as older adults?

Not under the American Geriatrics Society Beers Criteria, which apply to adults 65 and older and do not formally cover the 50-to-64 range [3]. The label's suicidality table, drawn from pooled antidepressant trials of about 77,000 adults and over 4,400 pediatric patients, shows one fewer case of suicidal thoughts or behavior per 1,000 treated patients aged 25 to 64 compared with placebo, and six fewer at 65 and older, with the excess concentrated under age 25 [1]. The boxed warning directs close monitoring of all treated patients for clinical worsening and new suicidal thoughts or behaviors, and the label specifies especially during the initial few months and at dose changes [1].

Medication load matters at this age. National survey data show 22.4% of US adults aged 40 to 79 used five or more prescription drugs in the past 30 days, and among adults 40 to 59 antidepressants were one of the most commonly used drug types [5].

Orthostatic hypotension and syncope

The label links trazodone's alpha-1 adrenergic blockade to postural hypotension [1]. In outpatient depression trials (trazodone 157 patients, placebo 158), hypotension was reported in 4% versus 0% and syncope in 5% versus 1% [1]. Drowsiness occurred in 41% versus 20% and dizziness or light-headedness in 28% versus 15% [1]. The label notes that taking trazodone with blood pressure medicines may require lowering the dose of the blood pressure drug [1].

QT prolongation and arrhythmia

The label states that trazodone prolongs the QT/QTc interval and may be arrhythmogenic in patients with preexisting cardiac disease [1]. Arrhythmias identified in clinical studies include isolated PVCs, ventricular couplets, tachycardia with syncope, and torsades de pointes [1]. Postmarketing reports of prolonged QT interval, torsades de pointes and ventricular tachycardia exist at doses of 100 mg/day or less with immediate-release tablets; the label notes that postmarketing reports come from a population of uncertain size, so frequency cannot always be estimated [1].

The label says to avoid trazodone in known QT prolongation, a history of cardiac arrhythmias, symptomatic bradycardia, hypokalemia or hypomagnesemia, congenital long QT, and the initial recovery phase of a myocardial infarction [1]. It also says to avoid combining trazodone with other QT-prolonging drugs such as quinidine, procainamide, amiodarone, sotalol, ziprasidone, chlorpromazine, thioridazine, or gatifloxacin [1]. With a strong CYP3A4 inhibitor such as itraconazole, ketoconazole, clarithromycin, or indinavir, the label says to consider a lower trazodone dose because exposure and the risk of adverse reactions, including arrhythmias, may increase [1].

Which interactions matter most?

CYP3A4 inhibitors and inducers. Trazodone is a CYP3A4 substrate, and CYP3A4 forms its active metabolite mCPP; in human liver microsomes and expressed enzymes only CYP3A4 produced mCPP [1][6]. A 2025 in vitro study found CYP2D6, CYP2C19 and flavin monooxygenases contribute to other, inactive metabolites, with CYP3A4 remaining primary [7]. The label says to consider a lower trazodone dose with a strong CYP3A4 inhibitor and a higher dose with a strong inducer such as rifampin, carbamazepine, phenytoin, or St. John's wort [1].

A study of 10 healthy volunteers given 50 mg trazodone with low-dose ritonavir (200 mg, four doses) found apparent oral clearance fell from 155 to 75 mL/min, half-life rose from 6.7 to 14.9 hours, and peak level rose from 842 to 1,125 ng/mL, with more sedation and fatigue; three participants had nausea, dizziness or hypotension, and one had syncope [8].

Serotonergic drugs. Serotonin syndrome can occur with trazodone alone, and risk rises with triptans, tricyclics, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John's wort, and MAOIs [1]. Signs include agitation, hallucinations, tachycardia, labile blood pressure, sweating, fever, tremor, rigidity, myoclonus, seizures, nausea, vomiting and diarrhea [1]. MAOI use within 14 days is the label's only contraindication, and 14 days must also pass after stopping trazodone before starting an MAOI [1].

Warfarin, antiplatelets and anticoagulants. The label warns of increased bleeding risk with aspirin, NSAIDs, other antiplatelets, warfarin and anticoagulants, and says prothrombin time may rise or fall with warfarin, so INR needs careful monitoring when trazodone is started or stopped [1].

Digoxin and phenytoin. Trazodone can raise levels of these narrow-therapeutic-index drugs; the label advises measuring levels before starting the combination and reducing their dose as necessary [1].

Alcohol and CNS depressants. Trazodone may enhance the effects of alcohol, barbiturates and other CNS depressants, and overdose deaths have occurred when it was taken with alcohol, chloral hydrate with diazepam, amobarbital, chlordiazepoxide, or meprobamate [1].

Dosing and pharmacokinetics

The label's dosing section describes depression only and gives no separate starting dose for adults in their fifties and sixties [1].

In healthy volunteers, after a single 100 mg oral dose in 8 subjects, terminal half-life was 7.3 plus or minus 0.8 hours and bioavailability about 63 to 65% [2]. Food lowered the peak level from 1.88 to 1.47 micrograms/mL and pushed the time to peak from 1.3 to 2.0 hours without changing total absorption [2]. Absorption was irregular in fasting subjects, and the investigators concluded trazodone should preferably be given after food [2].

Priapism

The label reports painful, prolonged erections and priapism, and tells men to stop the drug and get emergency care for any erection lasting more than 4 hours, painful or not [1]. It also says to use caution in sickle cell anemia, multiple myeloma, leukemia, and penile deformity such as Peyronie's disease [1].

Other label warnings worth knowing

Hyponatremia and SIADH are labeled risks, with higher risk in older adults [1]. The label flags mania or hypomania activation and advises screening for bipolar disorder first [1], potential impairment of judgment, thinking and motor skills [1], and angle-closure glaucoma in people with untreated narrow angles [1]. Discontinuation symptoms are also labeled, and the label specifies gradual dose reduction when the drug is discontinued [1].

What the label says to monitor

The label directs close monitoring of all treated patients for clinical worsening and emergent suicidal thoughts or behaviors, particularly in the first months and at dose changes [1]. It directs monitoring for serotonin syndrome, especially when other serotonergic drugs are started [1], and warns patients about the risk and symptoms of hypotension [1]. For patients on warfarin, the label calls for careful INR monitoring when trazodone is started or discontinued [1]; for digoxin and phenytoin, it calls for measuring levels before the combination and continuing to monitor [1].

Falls: what the evidence shows

A 2009 meta-analysis of 22 studies across 9 drug classes (79,081 participants in total) in adults older than 60 found antidepressants as a class associated with falls (unadjusted odds ratio 1.68, 95% credible interval 1.47 to 1.91; adjusted odds ratio 1.36, 1.13 to 1.76) [9]. That is a class-level association in people over 60, not a trazodone-specific figure and not specific to ages 50 to 64.